BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee C. Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists? Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.01.005] [Reference Citation Analysis]
2 Bugianesi E, Petta S. NAFLD/NASH. J Hepatol 2022:S0168-8278(22)00081-2. [PMID: 35513902 DOI: 10.1016/j.jhep.2022.02.006] [Reference Citation Analysis]
3 Kim W, Jeong HS, Kim SC, Choi CH, Lee KH. Chronic Alcohol Exposure of Cells Using Controlled Alcohol-Releasing Capillaries. Cells 2021;10:1120. [PMID: 34066517 DOI: 10.3390/cells10051120] [Reference Citation Analysis]
4 Zambon Azevedo V, Silaghi CA, Maurel T, Silaghi H, Ratziu V, Pais R. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. Front Nutr 2022;8:774030. [DOI: 10.3389/fnut.2021.774030] [Reference Citation Analysis]
5 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Cui B, Lin L, Wang B, Liu W, Sun C. Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer? Pharmacol Res 2021;175:106022. [PMID: 34883213 DOI: 10.1016/j.phrs.2021.106022] [Reference Citation Analysis]
7 Xin X, Cheng C, Bei-Yu C, Hong-Shan L, Hua-Jie T, Xin W, Zi-Ming A, Qin-Mei S, Yi-Yang H, Qin F. Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity. Front Nutr 2021;8:784354. [PMID: 34881283 DOI: 10.3389/fnut.2021.784354] [Reference Citation Analysis]
8 Yang YY, Xie L, Zhang NP, Zhou D, Liu TT, Wu J. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022. [PMID: 35190696 DOI: 10.1038/s41401-022-00860-3] [Reference Citation Analysis]
9 Venniyoor A, Al Farsi AA, Al Bahrani B. The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC). Cureus 2021;13:e17320. [PMID: 34557366 DOI: 10.7759/cureus.17320] [Reference Citation Analysis]
10 Spearman CW, Abdo A, Ambali A, Awuku YA, Kassianides C, Lesi OA, Ndomondo-Sigonda M, Onyekwere CA, Rwegasha J, Shewaye AB, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2021;6:1047-56. [PMID: 34508669 DOI: 10.1016/S2468-1253(21)00296-X] [Reference Citation Analysis]
11 Torre P, Motta BM, Sciorio R, Masarone M, Persico M. Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. Front Med (Lausanne) 2021;8:781567. [PMID: 34957156 DOI: 10.3389/fmed.2021.781567] [Reference Citation Analysis]
12 Gruneau L, Ekstedt M, Kechagias S, Henriksson M. Disease progression modelling for economic evaluation in non-alcoholic fatty liver disease - a systematic review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01153-8. [PMID: 34757199 DOI: 10.1016/j.cgh.2021.10.040] [Reference Citation Analysis]
13 Liu C, Wang YL, Yang YY, Zhang NP, Niu C, Shen XZ, Wu J. Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. FASEB J 2021;35:e21871. [PMID: 34473374 DOI: 10.1096/fj.202100939R] [Reference Citation Analysis]
14 Mauss S, Boesecke C. Communicable and noncommunicable liver disease in HIV. Curr Opin HIV AIDS 2021;16:152-5. [PMID: 33783404 DOI: 10.1097/COH.0000000000000675] [Reference Citation Analysis]
15 Ali ES, Rychkov GY, Barritt GJ. TRPM2 Non-Selective Cation Channels in Liver Injury Mediated by Reactive Oxygen Species. Antioxidants (Basel) 2021;10:1243. [PMID: 34439491 DOI: 10.3390/antiox10081243] [Reference Citation Analysis]
16 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Reference Citation Analysis]
17 Noureddin M. Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans. Hepatology 2021;74:9-11. [PMID: 33638172 DOI: 10.1002/hep.31777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Safadi R, Braun M, Francis A, Milgrom Y, Massarwa M, Hakimian D, Hazou W, Issachar A, Harpaz Z, Farbstein M, Itzhak I, Lev-Cohain N, Bareket-Samish A, Silverman MH, Fishman P. Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. Aliment Pharmacol Ther 2021;54:1405-15. [PMID: 34671996 DOI: 10.1111/apt.16664] [Reference Citation Analysis]
19 Zai W, Chen W, Liu H, Ju D. Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: From Molecular Mechanisms to Clinical Applications. Biomedicines 2021;9:1912. [PMID: 34944732 DOI: 10.3390/biomedicines9121912] [Reference Citation Analysis]
20 Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2021. [PMID: 34741169 DOI: 10.1038/s41577-021-00639-3] [Reference Citation Analysis]
21 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Reference Citation Analysis]
22 Cho Y, Rhee H, Kim Y, Lee M, Lee B, Kang ES, Cha B, Choi J, Lee Y. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). BMC Med 2022;20. [DOI: 10.1186/s12916-022-02288-2] [Reference Citation Analysis]
23 Liava C, Sinakos E. Semaglutide for nonalcoholic steatohepatitis: closer to a solution? Hepatobiliary Surg Nutr 2021;10:541-4. [PMID: 34430539 DOI: 10.21037/hbsn-21-231] [Reference Citation Analysis]
24 Mazzini GS, Augustin T, Noria S, Romero-Marrero C, Li N, Hameed B, Eisenberg D, Azagury DE, Ikramuddin S. ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis. Surg Obes Relat Dis 2021:S1550-7289(21)00548-7. [PMID: 34953742 DOI: 10.1016/j.soard.2021.11.015] [Reference Citation Analysis]
25 Motegi S, Tsuchiya A, Iwasawa T, Sato T, Kumagai M, Natsui K, Nojiri S, Ogawa M, Takeuchi S, Sakai Y, Miyagawa S, Sawa Y, Terai S. A novel prostaglandin I2 agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice. Inflamm Regen 2022;42:3. [PMID: 35101153 DOI: 10.1186/s41232-021-00191-6] [Reference Citation Analysis]
26 Calcagno DM, Chu A, Gaul S, Taghdiri N, Toomu A, Leszczynska A, Kaufmann B, Papouchado B, Wree A, Geisler L, Hoffman HM, Feldstein AE, King KR. NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH. Hepatology 2022. [PMID: 34997987 DOI: 10.1002/hep.32320] [Reference Citation Analysis]
27 Chen M, Xie Y, Gong S, Wang Y, Yu H, Zhou T, Huang F, Guo X, Zhang H, Huang R, Han Z, Xing Y, Liu Q, Tong G, Zhou H. Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol Res 2021;172:105849. [PMID: 34450307 DOI: 10.1016/j.phrs.2021.105849] [Reference Citation Analysis]
28 Helmstädter M, Kaiser A, Brunst S, Schmidt J, Ronchetti R, Weizel L, Proschak E, Merk D. Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics. J Med Chem 2021;64:9525-36. [PMID: 34165993 DOI: 10.1021/acs.jmedchem.1c00831] [Reference Citation Analysis]
29 Hirsova P, Bamidele AO, Wang H, Povero D, Revelo XS. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Front Endocrinol (Lausanne) 2021;12:760860. [PMID: 34777255 DOI: 10.3389/fendo.2021.760860] [Reference Citation Analysis]
30 Majumdar A, Verbeek J, Tsochatzis EA. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol 2021;61:98-105. [PMID: 34688168 DOI: 10.1016/j.coph.2021.09.007] [Reference Citation Analysis]
31 Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Holm Damgaard L, Buchholtz K, Skalshøi Kjær M, Balendran C, Myers RP, Loomba R, Noureddin M. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.003] [Reference Citation Analysis]
32 Quek J, Ng CH, Tang ASP, Chew N, Chan M, Khoo CM, Wei CP, Chin YH, Tay P, Lim G, Tan DJH, Lim WH, Chan KE, Teng M, Tan E, Tamaki N, Huang DQ, Siddiqui MS, Young DY, Noureddin M, Muthiah MD. Metabolic Associated Fatty Liver Disease (MAFLD) Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12,620,736 Individuals. Endocr Pract 2022:S1530-891X(22)00102-1. [PMID: 35364328 DOI: 10.1016/j.eprac.2022.03.016] [Reference Citation Analysis]
33 Bian H, Liu YM, Chen ZN. New avenues for NASH therapy by targeting ACC. Cell Metab 2022;34:191-3. [PMID: 35108509 DOI: 10.1016/j.cmet.2022.01.001] [Reference Citation Analysis]